on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.30 is realistic for this Co.
NYSE was in one of their Pr's
As we further carve-out our position as the partner of choice for any MANF-based product development effort, we expect that we will be successful in attracting the necessary financial commitments to move MANF into clinical testing based upon the success of experiments already underway. As we continue to show progress in Parkinson's disease, we will likely be in a good negotiating position with potential partners seeking to commercialize MANF both in Parkinson's and other medical conditions, which could create multiple partnering opportunities for the Company.
I think we could see .017 by EOD
If we do this could go to .03 tomorrow
IMO
This is way UNDERVALUED WITH THEIR PATENTS ALONE
I have a feeling we will beat it tomorrow
this is just a small JV in a testing process.....With this last PR- I think there may be a buyout worth over 30 million .....that puts us @ .30
As new and exciting proof-of-concept data for MANF in secondary therapeutic indications continues to be published by research laboratories throughout Europe, China, Japan and North America, the value of our intellectual property (“IP”) portfolio is steadily increasing. We are continually expanding our IP portfolio for MANF by filing and aggregating new patents
Amarantus BioSciences Co-Founders honored among 2012’s
“50 Most Important African-Americans in Technology
Amarantus Biosciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing new treatments and diagnostics for Parkinson’s disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com‘s 13th annual “50 Most Important African-Americans in Technology” for 2012. The selectees will gather in Washington, D.C. January 15th, 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).
Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development.
a 55 BILLION $ Company
we are still on the bottom too!
This is just the beginning
right now it's only valued at 1 million....
the real value of this company will soon be here!
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
Market Cap. of a million here is a joke......
A lot of money to be made here......Going to Be FUN FUN FUN
I see T*GG is on that list.....is was @.05 a little over a month ago now at .40 did you post this to their board too when it was at .07?
Very nice find Disney......looks like We're GOING TO DISNEYLANDLOL
Happy with today's close......no profit taking at EOD.....people see the real potential this Co. has
I see it....especially after the DD is done tonight....this Co. is heading due north
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF’s potential as a disease-modifying agent for the treatment of TBI.
Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
SUNNYVALE, Calif. – October 19, 2012 – Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF, today announced that it has appointed Clinton O. Allen to its Advisory Board. Mr. Allen will work with management at Amarantus to improve internal controls, prepare due diligence materials for investors and implement corporate governance best practices.
“Clinton Allen is a seasoned biopharmaceutical executive with exceptional leadership capabilities and experience in Big Pharma,” said Gerald E. Commissiong, President & CEO of Amarantus. “He will be a tremendous asset for the Company as we execute on our corporate strategy
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
“I am very excited to join Amarantus at this critical time in its growth cycle,” said Clinton O. Allen, newly appointed advisor to Amarantus. “The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order to meticulously evaluate proposals and make recommendations for future growth. About Amarantus
Amarantus BioSciences Co-Founders honored among 2012’s
“50 Most Important African-Americans in Technology”
SUNNYVALE, CA – September 25, 2012 – Amarantus Biosciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing new treatments and diagnostics for Parkinson’s disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com‘s 13th annual “50 Most Important African-Americans in Technology” for 2012. The selectees will gather in Washington, D.C. January 15th, 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).
Dr.
Amarantus BioSciences Announces Publication of Positive Animal Data for MANF in Myocardial Infarction
SUNNYVALE, CA – September 26, 2012 – Amarantus Biosciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson’s disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University’s (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled “Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion” reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
“The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value.”
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson’s disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson’s disease
). Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack
Ischemic Heart Disease is the most common cause of death in most Western countries, and a major cause of hospital admissions. There is limited evidence for population screening, but prevention is used both to prevent IHD and to decrease the risk of complications. Myocardial Infarctions are one of the leading causes of death for both men and women all over the world. Important risk factors are previous cardiovascular disease, older age, tobacco smoking, high blood levels of certain lipids and low levels of high density lipoprotein, diabetes, high blood pressure, obesity, chronic kidney disease, excessive alcohol consumption, and chronic high stress levels.
The common theme of the many forms of IHD, including myocardial infarction, that have been characterized is the pathway of apoptosis-related cell death associated with reperfusion related injuries. MANF has been shown to be robustly upregulated, and to protect heart muscle in reperfusion models of cardiac ischemia.
your welcome
I think we close above a penny before End of Day because we are expecting news on those interim results maybe after market or tomorrow
Anyone have a guess where this will ROCKET to if they announce AMGEN as a Partner?
wow it get real busy around here
I guess many want to make $$ lol
Amarantus’ license for NuroPro, our clinical-stage Parkinson’s disease diagnostic blood test, has several potential positive benefits for our MANF Parkinson’s program including the identification of patients most likely to respond to MANF treatment. We intend to immediately
pursue a partnering strategy for NuroPro and expect to update the marketplace once definitive agreements are reached. NuroPro could become a significant source of revenue for the Company within a relatively short period of time and its further development could have a major impact on the way Parkinson’s disease is diagnosed and managed by physicians.
In closing, the team at Amarantus has been working tirelessly to complete the goals we put out
As we further carve-out our position as the partner of choice for any MANF-based product development effort, we expect that we will be successful in attracting the necessary financial commitments to move MANF into clinical testing based upon the success of experiments already underway. As we continue to show progress in Parkinson’s disease, we will likely be in a good negotiating position with potential partners seeking to commercialize MANF both in Parkinson’s and other medical conditions, which could create multiple partnering opportunities for the Company.
Amarantus BioSciences Provides Update to Shareholders
SUNNYVALE, Calif. – October 10, 2012
As new and exciting proof-of-concept data for MANF in secondary therapeutic indications continues to be published by research laboratories throughout Europe, China, Japan and North America, the value of our intellectual property (“IP”) portfolio is steadily increasing. We are continually expanding our IP portfolio for MANF by filing and aggregating new patents
The best thing I think is there are most likely NO Side Efefectsbecause it is already produced in the body
Then of course their is Alzheimers too!
Their Patented Manf is going to revolutionize the Biotech industry
They already has positive research data that it will help with heart disease
The Department of Defense has already funded one of their partners 20 million for TBI (tramatic Brain Injury)
Parkinson cure is just the beginning .....MANF will cure many other diseases too! They have a medical breakthrough
just the 1st of MANY MANY MORE to come!
7 to 10 cents soon!
IMO
They even just had a former top level executive of Bristol Myers Squibb Join Their Team
A 55 BILLION $$$$ Co.